vs
ARTIVION, INC.（AORT）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是ARTIVION, INC.的1.9倍（$217.4M vs $116.0M），ARTIVION, INC.净利率更高（2.1% vs 1.4%，领先0.7%），ARTIVION, INC.同比增速更快（19.2% vs 0.5%），Rapid7, Inc.自由现金流更多（$36.4M vs $-7.9M），过去两年ARTIVION, INC.的营收复合增速更高（9.1% vs 3.0%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
AORT vs RPD — 直观对比
营收规模更大
RPD
是对方的1.9倍
$116.0M
营收增速更快
AORT
高出18.7%
0.5%
净利率更高
AORT
高出0.7%
1.4%
自由现金流更多
RPD
多$44.4M
$-7.9M
两年增速更快
AORT
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $217.4M |
| 净利润 | $2.4M | $3.1M |
| 毛利率 | 63.1% | 68.9% |
| 营业利润率 | 9.2% | 1.0% |
| 净利率 | 2.1% | 1.4% |
| 营收同比 | 19.2% | 0.5% |
| 净利润同比 | 114.7% | 44.1% |
| 每股收益（稀释后） | $0.06 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTRPD
| Q4 25 | $116.0M | $217.4M | ||
| Q3 25 | $113.4M | $218.0M | ||
| Q2 25 | $113.0M | $214.2M | ||
| Q1 25 | $99.0M | $210.3M | ||
| Q4 24 | $97.3M | $216.3M | ||
| Q3 24 | $95.8M | $214.7M | ||
| Q2 24 | $98.0M | $208.0M | ||
| Q1 24 | $97.4M | $205.1M |
净利润AORTRPD
| Q4 25 | $2.4M | $3.1M | ||
| Q3 25 | $6.5M | $9.8M | ||
| Q2 25 | $1.3M | $8.3M | ||
| Q1 25 | $-505.0K | $2.1M | ||
| Q4 24 | $-16.5M | $2.2M | ||
| Q3 24 | $-2.3M | $15.4M | ||
| Q2 24 | $-2.1M | $6.5M | ||
| Q1 24 | $7.5M | $1.4M |
毛利率AORTRPD
| Q4 25 | 63.1% | 68.9% | ||
| Q3 25 | 65.6% | 70.2% | ||
| Q2 25 | 64.7% | 70.6% | ||
| Q1 25 | 64.2% | 71.7% | ||
| Q4 24 | 63.2% | 69.5% | ||
| Q3 24 | 63.7% | 70.6% | ||
| Q2 24 | 64.6% | 70.7% | ||
| Q1 24 | 64.6% | 70.3% |
营业利润率AORTRPD
| Q4 25 | 9.2% | 1.0% | ||
| Q3 25 | 11.1% | 2.7% | ||
| Q2 25 | 7.4% | 1.6% | ||
| Q1 25 | 2.2% | -0.0% | ||
| Q4 24 | 2.7% | 3.4% | ||
| Q3 24 | 4.6% | 6.0% | ||
| Q2 24 | 6.6% | 2.5% | ||
| Q1 24 | 26.0% | 4.7% |
净利率AORTRPD
| Q4 25 | 2.1% | 1.4% | ||
| Q3 25 | 5.7% | 4.5% | ||
| Q2 25 | 1.2% | 3.9% | ||
| Q1 25 | -0.5% | 1.0% | ||
| Q4 24 | -16.9% | 1.0% | ||
| Q3 24 | -2.4% | 7.2% | ||
| Q2 24 | -2.2% | 3.1% | ||
| Q1 24 | 7.7% | 0.7% |
每股收益（稀释后）AORTRPD
| Q4 25 | $0.06 | $0.05 | ||
| Q3 25 | $0.13 | $0.15 | ||
| Q2 25 | $0.03 | $0.13 | ||
| Q1 25 | $-0.01 | $0.03 | ||
| Q4 24 | $-0.40 | $0.08 | ||
| Q3 24 | $-0.05 | $0.21 | ||
| Q2 24 | $-0.05 | $0.09 | ||
| Q1 24 | $0.18 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $474.7M |
| 总债务越低越好 | $215.1M | — |
| 股东权益账面价值 | $448.2M | $154.7M |
| 总资产 | $884.8M | $1.7B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AORTRPD
| Q4 25 | $64.9M | $474.7M | ||
| Q3 25 | $73.4M | $407.1M | ||
| Q2 25 | $53.5M | $511.7M | ||
| Q1 25 | $37.7M | $493.5M | ||
| Q4 24 | $53.5M | $521.7M | ||
| Q3 24 | $56.2M | $443.7M | ||
| Q2 24 | $55.0M | $442.6M | ||
| Q1 24 | $51.1M | $411.7M |
总债务AORTRPD
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTRPD
| Q4 25 | $448.2M | $154.7M | ||
| Q3 25 | $438.7M | $127.2M | ||
| Q2 25 | $419.9M | $90.4M | ||
| Q1 25 | $294.3M | $52.7M | ||
| Q4 24 | $276.2M | $17.7M | ||
| Q3 24 | $304.7M | $-5.1M | ||
| Q2 24 | $295.1M | $-52.6M | ||
| Q1 24 | $295.0M | $-86.4M |
总资产AORTRPD
| Q4 25 | $884.8M | $1.7B | ||
| Q3 25 | $857.7M | $1.7B | ||
| Q2 25 | $838.4M | $1.6B | ||
| Q1 25 | $791.2M | $1.6B | ||
| Q4 24 | $789.1M | $1.7B | ||
| Q3 24 | $803.1M | $1.6B | ||
| Q2 24 | $789.5M | $1.5B | ||
| Q1 24 | $784.0M | $1.5B |
负债/权益比AORTRPD
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $36.4M |
| 自由现金流率自由现金流/营收 | -6.9% | 16.8% |
| 资本支出强度资本支出/营收 | 23.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 8.06× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $839.0K | $146.2M |
8季度趋势，按日历期对齐
经营现金流AORTRPD
| Q4 25 | $19.6M | $37.6M | ||
| Q3 25 | $22.3M | $39.0M | ||
| Q2 25 | $15.0M | $47.5M | ||
| Q1 25 | $-17.0M | $29.8M | ||
| Q4 24 | $10.1M | $63.8M | ||
| Q3 24 | $11.5M | $44.0M | ||
| Q2 24 | $6.1M | $32.9M | ||
| Q1 24 | $-5.5M | $31.1M |
自由现金流AORTRPD
| Q4 25 | $-7.9M | $36.4M | ||
| Q3 25 | $17.7M | $34.8M | ||
| Q2 25 | $11.7M | $46.6M | ||
| Q1 25 | $-20.6M | $28.4M | ||
| Q4 24 | $8.7M | $62.6M | ||
| Q3 24 | $7.8M | $42.6M | ||
| Q2 24 | $3.6M | $32.6M | ||
| Q1 24 | $-9.1M | $30.4M |
自由现金流率AORTRPD
| Q4 25 | -6.9% | 16.8% | ||
| Q3 25 | 15.6% | 16.0% | ||
| Q2 25 | 10.4% | 21.8% | ||
| Q1 25 | -20.8% | 13.5% | ||
| Q4 24 | 9.0% | 28.9% | ||
| Q3 24 | 8.2% | 19.9% | ||
| Q2 24 | 3.7% | 15.7% | ||
| Q1 24 | -9.3% | 14.8% |
资本支出强度AORTRPD
| Q4 25 | 23.7% | 0.5% | ||
| Q3 25 | 4.1% | 1.9% | ||
| Q2 25 | 2.9% | 0.4% | ||
| Q1 25 | 3.7% | 0.6% | ||
| Q4 24 | 1.5% | 0.5% | ||
| Q3 24 | 3.8% | 0.6% | ||
| Q2 24 | 2.6% | 0.1% | ||
| Q1 24 | 3.7% | 0.3% |
现金转化率AORTRPD
| Q4 25 | 8.06× | 12.01× | ||
| Q3 25 | 3.42× | 3.97× | ||
| Q2 25 | 11.16× | 5.70× | ||
| Q1 25 | — | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | -0.73× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
